Allschwil, Switzerland, January 19, 2024

Original post:
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates from its oral presentation at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024) in San Diego, California.

Link:
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval

Read the original:
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced that it will host a virtual KOL event on Thursday, January 25, 2024 at 10:00 am ET to briefly review, then discuss the topline results from the Phase IIb PORTICO study evaluating vafidemstat in Borderline Personality Disorder (BPD). To register for the event, click here.

Here is the original post:
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator -

See the original post:
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

TEL AVIV, Israel, Jan. 19, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it entered, as lender, into a bridge loan agreement (the "Agreement) with a leading vehicle importer company in Israel, as borrower (the "Target Company"), pursuant to which the Target Company received a bridge loan (the “Bridge Loan”) in the amount of $1.4 million, further to the previously-announced non-binding letter of intent (the “LOI”) for the Company to acquire the Target Company (the “Acquisition”).

See the original post here:
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million

Basel, January 19, 2024 – Novartis today presented data from the Phase III NETTER-2 trial showing that Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus long-acting release (LAR) octreotide reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose octreotide LAR alone1. Data were presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.

Read more:
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced...

Company announcement no. 1 – 24 19 January 2024

See the article here:
Change of management at NTG Nordic Transport Group A/S

Company announcement – No. 5 / 2024

Originally posted here:
Zealand Pharma major shareholder announcement: J O Hambro Capital Management

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the reinspection of Alvotech’s facility in Iceland by the U.S. Food and Drug Administration (FDA) which started on January 10, 2024, has been concluded. Following the FDA inspection, Alvotech received a form 483 with one observation. Alvotech expects to provide the FDA with a response in the following days.

See the article here:
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04

Regulated Information - Denominator

Read the original here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Link:
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,500 shares of its common stock to nine newly-hired employees, with a grant date of January 18, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

Go here to see the original:
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement

Read the rest here:
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Read more:
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

– Transaction aligns to Coherus’ strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time –

See the original post here:
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

ORION CORPORATION STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 11 JANUARY 2024 at 14.15 EET

Continue reading here:
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31...

Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023.

Read the rest here:
QIAGEN N.V. to release results for Q4 2023 and hold webcast

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-40 reverse stock split, to be effective at 12:01 a.m. Eastern Standard Time Tuesday, January 16, 2024. TransCode common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Tuesday, January 16, 2024, under the current trading symbol, “RNAZ.” The reverse stock split was approved by TransCode’s stockholders on January 8, 2024, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

See the article here:
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

DALLAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASD:MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, announces the enrollment of the first patient in the pivotal study to validate DeepView AI® using its proprietary imaging technology for burn size and healing assessment. This pivotal study is expected to be the final clinical trial before seeking FDA marketing authorization for the burn indication in 2025 and will be conducted in burn centers and emergency departments across the US, enrolling both adults and pediatric patients.

See the article here:
Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries